Le Lézard
Classified in: Health
Subjects: ACC, MAT

Stem Holdings d/b/a Driven By Stem Reports Record Gross Revenue of $12.4 Million for CY21 First Quarter Results


BOCA RATON, Fla., May 18, 2021 /PRNewswire/ -- Stem Holdings, Inc., d/b/a Driven By Stem ("Stem" or the "Company"), a leading omnichannel, vertically-integrated cannabis branded products and technology company with state-of-the-art cultivation, processing, extraction, retail, distribution, and delivery-as-a-service (DaaS) operations throughout the United States, today reported its financial results for the first calendar quarter ended March 31, 2021.

Highlights for the quarter ended March 31, 2021:

Operational Updates

Management Commentary 
"Our record sales and the beginning of the successful integration of Driven Deliveries Inc. ("Driven") has positioned us for greater growth as we expand the footprint of our retail, delivery, and branded product operations in high-growth markets," stated Adam Berk, CEO of the Company. "Full integration and streamlined execution and expansion of Driven's technology will continue over the next six months, to be completed by the end of 2021. We are leveraging our combined strength by simultaneously increasing market share of our own retail operations, as well as our branded products," he continued. "Our plans for expansion in Michigan both at retail and with Budee delivery by Labor Day, as well as our ongoing efforts in New York, bode well for accretive growth throughout 2021. We are excited about our progress and driving synergies for continued growth in 2022."

Mr. Berk continued, "We have continued to strengthen our balance sheet and to add strong management talent to our team to ensure that we can manage our 'Farm-to-Hometm' strategy in all current and expanded markets. We also continue to improve gross margin and cash conversion as we continue to support our initiatives building shareholder value."

Financing
On April 23, 2021, the Company closed a C$10.3 million public offering announced in December 2020 (the Offering"), of units of the Company (the "Units") at a price of $.55 per Unit.  Each Unit was comprised of one share of common stock of the Company and one share purchase warrant of the Company (a "Warrant"). Each Warrant is exercisable at an exercise price of C$0.68 until April 23, 2023. The Offering was led by Canaccord Genuity Corp. The offering included a short-form prospectus and an effective S-1.

Expansion of Consumer Packaged Goods Business

Retail Business Development

The Company continues its plans for accretive new product innovation with a queue of innovative products scheduled for launch throughout 2021. 

About Stem Holdings, Inc.
Stem is a leading omnichannel, vertically-integrated cannabis branded products and technology company with state-of-the-art cultivation, processing, extraction, retail, distribution, and delivery-as-a-service (DaaS) operations throughout the United States . Stem's family of award-winning brands includes TJ's Gardenstm, TravisxJamestm, and Yerba Buenatm flower and extracts; Cannavoretm edible confections; Doseologytm a CBD mass-market brand launching in 2021; as well as DaaS brands Budeetm and Ganjarunnertm through the acquisition of Driven Deliveries. Budeetm and Ganjarunnertm e-commerce platforms provide direct-to consumer proprietary logistics and an omnichannel UX (user experience)/CX (customer experience).

Forward-Looking Statements 
This press release contains forward-looking statements and information that are based on the beliefs of management and reflect the Company's current expectations.  When used in this press release, the words "estimate", "project", "belief", "anticipate", "intend", "expect", "plan", "predict", "may" or "should" and the negative of these words or such variations thereon or comparable terminology are intended to identify forward-looking statements and information. The forward-looking statements and information in this press release includes information relating to: (i) the implementation of the Company's business plan; (ii) the expansion of Stem's brands and products into other markets; (iii) expected improvements to productivity; (iv) the expected launch of new brands and products by Stem; and (v) expected full integration of Driven into the business of Stem. 

By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.  Such factors include, among others, the following risks: risks associated with the implementation of the Company's business plan and matters relating thereto, risks associated with the cannabis industry, competition, regulatory change, the need for additional financing, reliance on key personnel, the potential for conflicts of interest among certain officers or directors, insurance, intellectual property and reliable supply chains; and risks related to the Company and its business generally. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made, and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change.  Investors are cautioned against attributing undue certainty to forward-looking statements.

Non-GAAP Measures
This news release contains references to certain measures that are not defined under a body of generally accepted accounting principles for publicly accountable entities in the United States, which is commonly referred to as "GAAP" or "U.S. GAAP". For this purpose, a non-GAAP financial measure is generally defined as one that purports to measure historical or future financial performance, financial position or cash flows but excludes or includes amounts that would not be so adjusted in the most comparable GAAP measure. These non-GAAP measures are not recognized measures under GAAP, do not have a standardized meaning prescribed by GAAP and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement GAAP measures by providing further understanding of the Company's results of operations from management's perspective. Accordingly, they should not be considered in isolation nor as a substitute for analysis of the Company's financial information reported under U.S. GAAP.

The Company uses non-GAAP measures, including adjusted EBITDA to provide investors with supplemental measures of its operating performance and thus highlight trends in its core business that may not otherwise be apparent when relying solely on GAAP measures. The Company believes that investors, securities analysts and other interested parties frequently use non-GAAP measures in the evaluation of issuers. Management also uses non-GAAP measures in order to facilitate operating performance comparisons from period to period and assess the Company's ability to meet its future debt service, capital expenditure and working capital requirements.

The term "adjusted EBITDA" consists of net (loss) income and excludes interest, taxes, depreciation, amortization, share-based compensation, impairment of assets, acquisition costs, legal settlement costs, restructuring charges, and adjustments for fair value of biological assets, warrant liabilities, and stock appreciation rights. The most directly comparable measure to adjusted EBITDA calculated in accordance with GAAP is net (loss) income.

For further information, please contact:
Media Contact: 
Mauria Betts 
STEM HOLDINGS, INC. 
[email protected] 971.319.0303

Investor Contact: 
Valter Pinto / Elizabeth Barker 
[email protected] 
212.896.1254 / 212-896-1203 

SOURCE Stem Holdings, Inc.


These press releases may also interest you

at 17:50
The global breast tissue expander market size is estimated to grow by USD 282.4 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  6.78%  during the forecast period. Increasing prevalence of breast cancer is...

at 17:50
The global sleep apnea implants market size is estimated to grow by USD 401.75 thousand from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 15.2% during the forecast period. Increasing prevalence of sleep apnea and...

at 17:45
The global implantable medical devices market size is estimated to grow by USD 53.5 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 8.08% during the forecast period. Rise in number of people with chronic...

at 17:35
The global transplant box market size is estimated to grow by USD 2.39 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  10.87%  during the forecast period. Increasing prevalence of chronic disorders is...

at 17:31
DelveInsight's BK Virus Infection Market Insights report includes a comprehensive understanding of current treatment practices, BK virus infection emerging drugs, market share...

at 17:30
The global dermatology devices market  size is estimated to grow by USD 154.23 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  9.45%  during the forecast period.  Increasing prevalence of skin...



News published on and distributed by: